Ambu will be distributing Intronix Technologies' Innovative Myoguide™ System Worldwide

News provided by

Oct 27, 2014, 01:05 ET

TORONTO, Oct. 27, 2014 /PRNewswire/ -- Ambu, a leading global supplier of medical devices, has signed a distribution agreement with Intronix Technologies. Intronix Technologies' innovative Myoguide EMG guided injection system will be available through Ambu's worldwide network of distributors, which already services Ambu's customers locally.

The revolutionary Myoguide™ Needle EMG Guided Injection System has breakthrough technology that gives practitioners a superior way to deliver targeted injections. Myoguide™ uses the patient's muscle signals to provide ongoing visual and audio feedback, during the needle insertion, to help find focal areas responsible for pain and spasticity.

Developed by the Canadian-based innovator, Intronix Technologies Corp. (http://www.intronixtech.com), the Myoguide™ system detects critical information about the tissues targeted for injection. It then provides instant reporting that increases the odds for successful, accurately measured injections, thus helping minimize mistakes, inaccurate dosages and potential side effects.

Myoguide™ is most frequently used to help direct injections with Botox® and similar drugs. Myoguide™ uses an innovative signal display and high fidelity audio feedback to help clinicians find the optimal injection sites to help manage myofascial pain, spasticity, fibromyalgia, and even cosmetics injections.

"We are pleased to join forces with Ambu to provide our clinician customers with Ambu's Neuroline hypodermic needle electrodes and surface electrode product lines. This will present a complete clinical package for clinicians managing myofascial pain, movement disorders, spasticity and cosmetic applications," says Dr. Evan Friedman, President of Intronix Technologies. "Ambu has a great reputation of manufacturing and distributing excellent medical devices, and we are proud to be a part of the team. Ambu has a solid distribution network and will give Myoguide full exposure throughout Ambu's extensive worldwide healthcare community."

Intronix (booth 306) and Ambu USA (booth 404) will be at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly, November 13–16, 2014 at the San Diego Convention Center.

About Ambu
Since 1937, breakthrough ideas have fueled Ambu's work on bringing efficient healthcare solutions to life. This is what they create within their fields of excellence – Anaesthesia, Patient Monitoring & Diagnostics, and Emergency Care. Millions of patients and healthcare professionals worldwide depend on the functionality and performance of Ambu products. Ambu are dedicated to improving patient safety. With corporate headquarters in Ballerup, Denmark, Ambu employs approximately 2,250 people worldwide. For additional information about Ambu, please refer to http://www.ambu.com.

Contact:

About Intronix Technologies Corporation
Located just outside Toronto, Ontario, Intronix Technologies Corporation designs and produces progressive portable medical devices for neuromuscular diagnostics and treatment delivery. Its innovations in injection guidance provide technology that drives clinical solutions to deliver confidence, improve workflow efficiency, and provide a better patient experience. Intronix Technologies is known for its exceptional equipment, plus its comprehensive customer-support programs that are developed to maximize the lifecycle value of equipment through responsive service maintenance and significant software support. For additional information about Intronix, please refer to www.intronixtech.com.

Contact:
Dr. Evan Friedman
President, Intronix Technologies Corporation
+01-905-951-3361
Email

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ambu-will-be-distributing-intronix-technologies-innovative-myoguide-system-worldwide-177501442.html

SOURCE Intronix Technologies Corporation